tetano
Editor, Senior Moderator
Cureus
. 2021 Nov 16;13(11):e19616.
doi: 10.7759/cureus.19616. eCollection 2021 Nov.
De-novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19
Elio Junior Feghali[SUP] 1 [/SUP], Maha Zafar[SUP] 2 [/SUP], Sidrah Abid[SUP] 3 [/SUP], Dominick Santoriello[SUP] 4 [/SUP], Swati Mehta[SUP] 3 [/SUP]
Affiliations
Abstract
Antineutrophil cytoplasmic antibody (ANCA) is a systemic autoimmune disorder characterized by antibodies directed against small- and moderate-sized vessels. While there are few reported cases of autoimmune illnesses associated with influenza vaccination, two cases of de-novo anti-proteinase (PR3) ANCA-associated pauci immune glomerulonephritis are reported after the mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine. Here, we report the third case of ANCA-associated glomerulonephritis after the mRNA-1273 COVID-19 vaccine. Our patient presented with acute kidney injury and sub-nephrotic proteinuria four days after receiving the second dose of the COVID vaccine. He was found to have elevated c-ANCA and anti-PR3 antibodies. Renal biopsy confirmed focal necrotizing and diffuse crescentic glomerulonephritis. He was diagnosed with pauci immune glomerulonephritis. The patient achieved remission 10 weeks after the diagnosis with successful treatment.
Keywords: acute kidney injury; coronavirus disease (covid-19); glomerulonephritis; mrna-1273 vaccine; pr3-anca.
. 2021 Nov 16;13(11):e19616.
doi: 10.7759/cureus.19616. eCollection 2021 Nov.
De-novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19
Elio Junior Feghali[SUP] 1 [/SUP], Maha Zafar[SUP] 2 [/SUP], Sidrah Abid[SUP] 3 [/SUP], Dominick Santoriello[SUP] 4 [/SUP], Swati Mehta[SUP] 3 [/SUP]
Affiliations
- PMID: 34956751
- PMCID: PMC8675571
- DOI: 10.7759/cureus.19616
Abstract
Antineutrophil cytoplasmic antibody (ANCA) is a systemic autoimmune disorder characterized by antibodies directed against small- and moderate-sized vessels. While there are few reported cases of autoimmune illnesses associated with influenza vaccination, two cases of de-novo anti-proteinase (PR3) ANCA-associated pauci immune glomerulonephritis are reported after the mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine. Here, we report the third case of ANCA-associated glomerulonephritis after the mRNA-1273 COVID-19 vaccine. Our patient presented with acute kidney injury and sub-nephrotic proteinuria four days after receiving the second dose of the COVID vaccine. He was found to have elevated c-ANCA and anti-PR3 antibodies. Renal biopsy confirmed focal necrotizing and diffuse crescentic glomerulonephritis. He was diagnosed with pauci immune glomerulonephritis. The patient achieved remission 10 weeks after the diagnosis with successful treatment.
Keywords: acute kidney injury; coronavirus disease (covid-19); glomerulonephritis; mrna-1273 vaccine; pr3-anca.